JP2012525432A - ヘレグリン共役型ｈｅｒ３と免疫反応性の改善された抗体 - Google Patents

ヘレグリン共役型ｈｅｒ３と免疫反応性の改善された抗体 Download PDF

Info

Publication number
JP2012525432A
JP2012525432A JP2012508753A JP2012508753A JP2012525432A JP 2012525432 A JP2012525432 A JP 2012525432A JP 2012508753 A JP2012508753 A JP 2012508753A JP 2012508753 A JP2012508753 A JP 2012508753A JP 2012525432 A JP2012525432 A JP 2012525432A
Authority
JP
Japan
Prior art keywords
antibody
her3
heregulin
antibodies
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012508753A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012525432A5 (enExample
Inventor
ブルース キート
ローレンス エム． カウバー
エレン ジェイ． コラリニ
オリット フォード
ギゼット スパリンデ
マルヤン ファトラヒ
ハン グエン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Trellis Bioscience Inc
Original Assignee
Trellis Bioscience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trellis Bioscience Inc filed Critical Trellis Bioscience Inc
Publication of JP2012525432A publication Critical patent/JP2012525432A/ja
Publication of JP2012525432A5 publication Critical patent/JP2012525432A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2012508753A 2009-04-29 2010-04-29 ヘレグリン共役型ｈｅｒ３と免疫反応性の改善された抗体 Pending JP2012525432A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17367009P 2009-04-29 2009-04-29
US61/173,670 2009-04-29
PCT/US2010/033058 WO2010127181A1 (en) 2009-04-29 2010-04-29 Improved antibodies immunoreactive with heregulin-coupled her3

Publications (2)

Publication Number Publication Date
JP2012525432A true JP2012525432A (ja) 2012-10-22
JP2012525432A5 JP2012525432A5 (enExample) 2013-05-30

Family

ID=43032570

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012508753A Pending JP2012525432A (ja) 2009-04-29 2010-04-29 ヘレグリン共役型ｈｅｒ３と免疫反応性の改善された抗体

Country Status (7)

Country Link
US (3) US8362215B2 (enExample)
EP (1) EP2425009A4 (enExample)
JP (1) JP2012525432A (enExample)
AU (1) AU2010242914B2 (enExample)
CA (1) CA2759792A1 (enExample)
IL (1) IL216014A0 (enExample)
WO (1) WO2010127181A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016503294A (ja) * 2012-11-08 2016-02-04 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Ｈｅｒ３のベータヘアピンに結合するｈｅｒ３抗原結合タンパク質

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12012501157A1 (en) 2009-12-22 2012-10-29 Roche Glycart Ag Anti-her3 antibodies and uses thereof
US8481687B2 (en) 2010-04-09 2013-07-09 Aveo Pharmaceuticals, Inc. Anti-ErbB3 antibodies
SG187908A1 (en) 2010-08-20 2013-03-28 Novartis Ag Antibodies for epidermal growth factor receptor 3 (her3)
TW201302793A (zh) * 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
KR101862832B1 (ko) 2010-11-01 2018-05-30 심포젠 에이/에스 Ｐａｎ―ｈｅｒ 항체 조성물
BR112013022882A2 (pt) 2011-03-11 2016-12-20 Merrimack Pharmaceuticals Inc uso de inibidores de receptores da família egfr no tratamento de cânceres de mama hormônio-refratários
JP2014509593A (ja) 2011-03-15 2014-04-21 メリマック ファーマシューティカルズ インコーポレーティッド ＥｒｂＢ経路阻害剤に対する耐性の克服
BR112013027021A2 (pt) 2011-04-19 2016-11-29 Merrimack Pharmaceuticals Inc anticorpos anti-igf-1r e anti-erbb3 monoespecíficos e biespecíficos
JP2014516960A (ja) * 2011-05-19 2014-07-17 インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） 抗ヒトｈｅｒ３抗体及びその使用
PH12014500483A1 (en) 2011-09-30 2014-04-14 Regeneron Pharma Anti-erbb3 antibodies and uses thereof
US9273143B2 (en) 2011-09-30 2016-03-01 Regeneron Pharmaceuticals, Inc. Methods and compositions comprising a combination of an anti-ErbB3 antibody and an anti-EGFR antibody
AU2012318541B2 (en) 2011-10-06 2018-04-12 Aveo Pharmaceuticals, Inc. Predicting tumor response to anti-ERBB3 antibodies
MX350957B (es) * 2011-11-23 2017-09-27 Medimmune Llc Moleculas de union especificas para her3 y usos de las mismas.
KR102083957B1 (ko) 2011-12-05 2020-03-04 노파르티스 아게 표피 성장 인자 수용체 3 (her3)에 대한 항체
JP2015500829A (ja) * 2011-12-05 2015-01-08 ノバルティス アーゲー 上皮細胞増殖因子受容体３（ｈｅｒ３）のドメインｉｉに対するｈｅｒ３の抗体
TW201331225A (zh) * 2011-12-05 2013-08-01 Novartis Ag 針對表皮生長因子受體３（ｈｅｒ３）之域ｉｉｉ及域ｉｖ之ｈｅｒ３抗體
US9725511B2 (en) 2012-11-08 2017-08-08 Hoffmann-La Roche Inc. Anti-HER3/HER4 antibodies binding to the beta-hairpin of HER3 and the beta-hairpin of HER4
AR094403A1 (es) 2013-01-11 2015-07-29 Hoffmann La Roche Terapia de combinación de anticuerpos anti-her3
JP6357113B2 (ja) * 2013-02-08 2018-07-11 株式会社医学生物学研究所 ヒトｎｒｇ１タンパク質に対する抗体
EP2821071A1 (en) 2013-07-04 2015-01-07 Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) Compounds for breast cancer treatment
WO2015048008A2 (en) 2013-09-24 2015-04-02 Medimmune, Llc Binding molecules specific for her3 and uses thereof
WO2015066543A1 (en) * 2013-11-01 2015-05-07 Board Of Regents, The University Of Texas System Targeting her2 and her3 with bispecific antibodies in cancerous cells
EP3087394A2 (en) 2013-12-27 2016-11-02 Merrimack Pharmaceuticals, Inc. Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies
US10745490B2 (en) 2014-04-11 2020-08-18 Celldex Therapeutics, Inc. Anti-ErbB antibodies and methods of use thereof
EP3143048B1 (en) 2014-05-14 2019-08-28 F. Hoffmann-La Roche AG Anti-her3 antibodies binding to the beta-hairpin of her3
US10184006B2 (en) 2015-06-04 2019-01-22 Merrimack Pharmaceuticals, Inc. Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors
CN108602890A (zh) 2015-12-11 2018-09-28 瑞泽恩制药公司 用于减少或预防对egfr和/或erbb3阻滞剂具有抗性的肿瘤生长的方法
WO2019185164A1 (en) 2018-03-29 2019-10-03 Hummingbird Bioscience Holdings Pte. Ltd. Her3 antigen-binding molecules

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007077028A2 (en) * 2005-12-30 2007-07-12 U3 Pharma Ag Antibodies directed to her-3 and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5183884A (en) 1989-12-01 1993-02-02 United States Of America Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
US5968511A (en) 1996-03-27 1999-10-19 Genentech, Inc. ErbB3 antibodies
AU727606B2 (en) * 1996-07-12 2000-12-14 Genentech Inc. Gamma-heregulin
US20090087878A9 (en) * 1999-05-06 2009-04-02 La Rosa Thomas J Nucleic acid molecules associated with plants
US7125680B2 (en) * 2001-07-27 2006-10-24 The Regents Of The University Of California Methods and materials for characterizing and modulating interaction between heregulin and HER3
EP1283053A1 (en) 2001-08-09 2003-02-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibitors of HER3 activity
ATE525398T1 (de) 2002-05-10 2011-10-15 Medimmune Inc Epha2 monoklonale antikörper und deren anwendungsverfahren
US7501494B2 (en) 2003-01-15 2009-03-10 United Biomedical, Inc. Designed deimmunized monoclonal antibodies for protection against HIV exposure and treatment of HIV infection
US7531649B2 (en) 2003-07-18 2009-05-12 The Regents Of The University Of California Aptamers to human epidermal growth factor receptor-3
US7413868B2 (en) 2003-11-05 2008-08-19 Trellis Bioscience, Inc. Use of particulate labels in bioanalyte detection methods
LT1931710T (lt) 2005-08-31 2017-03-27 Merck Sharp & Dohme Corp. Rekombinantiniai anti-il-23 antikūnai

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007077028A2 (en) * 2005-12-30 2007-07-12 U3 Pharma Ag Antibodies directed to her-3 and uses thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016503294A (ja) * 2012-11-08 2016-02-04 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Ｈｅｒ３のベータヘアピンに結合するｈｅｒ３抗原結合タンパク質

Also Published As

Publication number Publication date
US9321839B2 (en) 2016-04-26
US8828388B2 (en) 2014-09-09
EP2425009A4 (en) 2013-01-23
WO2010127181A1 (en) 2010-11-04
US8362215B2 (en) 2013-01-29
US20140370548A1 (en) 2014-12-18
AU2010242914A1 (en) 2011-11-24
AU2010242914B2 (en) 2014-11-13
CA2759792A1 (en) 2010-11-04
US20100310557A1 (en) 2010-12-09
EP2425009A1 (en) 2012-03-07
IL216014A0 (en) 2012-01-31
US20130122000A1 (en) 2013-05-16

Similar Documents

Publication Publication Date Title
US8362215B2 (en) Antibodies immunoreactive with heregulin-coupled HER3
US9932407B2 (en) Stem cell enhancing therapeutics
JP5823858B2 (ja) 抗ｖｅｇｆ抗体
TWI695013B (zh) 抗體、產生該抗體之融合瘤、包含該抗體之藥學組成物及其用途
KR101468397B1 (ko) 유방암을 치료하는 방법
JP2024026309A (ja) Ｂ７－ｈ４抗体及びその使用方法
EA015589B1 (ru) Антитела против миостатина и их применение
CN102791735A (zh) 抗前胃泌素的单克隆抗体及其用途
CN109369808A (zh) 用于治疗ror1癌症并抑制转移的抗体和疫苗
JP2015501639A (ja) 抗ｃｄ９８抗体およびその使用方法
CN102046803B (zh) 碱性成纤维细胞生长因子的单克隆抗体
KR20140116525A (ko) 항cxcr3 항체
US20200291130A1 (en) Antibodies for the treatment of erbb-2/erbb-3 positive tumors
EP3397964B1 (en) Compositions and methods for detecting and treating ovarian cancer
WO2014169494A1 (zh) 特异性识别egfr突变蛋白的单克隆抗体、制备方法及其应用
US20220289840A1 (en) Antibodies To Cell Adhesion Molecule-Related/Down-Regulated By Oncogenes (CDON) And Uses Thereof
RU2706967C2 (ru) Антитело к igf-1r и его применение для диагностики рака
RU2706959C2 (ru) Антитело к igf-1r и его применение для диагностики рака
US20250092124A1 (en) Antibody molecule against growth and differentiation factor 15 and use thereof
US20240174741A1 (en) Il-38-specific antibodies
WO2024088386A1 (en) Antibody, antigen-binding fragment thereof, and pharmaceutical use thereof
AU2013227987A1 (en) Anti-hepcidin antibodies and methods of use

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130410

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130410

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140811

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141111

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150302

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20150602